Price T Rowe Associates Inc Karyopharm Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 134,700 shares of KPTI stock, worth $80,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
134,700
Previous 97,100
38.72%
Holding current value
$80,820
Previous $84,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding KPTI
# of Institutions
98Shares Held
57.6MCall Options Held
258KPut Options Held
81.2K-
Vanguard Group Inc Valley Forge, PA7.65MShares$4.59 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY5.55MShares$3.33 Million0.36% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$3.06 Million0.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$2.59 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$2.5 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $47.9M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...